London – 61 regulators from 25 countries made progress in improving the generic and biosimilar medicines regulatory landscape for patient needs at the 15th Regulatory and Scientific Affairs Conference organised by the European Generic and Biosimilar medicines Association (EGA).

The EMA/HMA Strategy 2020, complemented by the CMDh 2020 Strategy Paper, will pursue operational excellence in the EU Regulatory Network and engagement in international regulatory platforms which will ultimately deliver greater value to public health.

The generic and biosimilar medicines industries presented a number of regulatory improvements in the EGA Regulatory Efficiency report in support of the 2020 strategies.

Promoting high-standard global regulatory convergence, supporting a single development programme for generic and biosimilar medicines and optimising the scope of regulatory processes supported by telematics tools will contribute to better access for better health by 2020.

Adrian van den Hoven, Director General of the European Generic and Biosimilar medicines Association (EGA) said “this event provides an invaluable platform for manufacturers, regulators and stakeholders to improve regulatory efficiency so that our industries can deliver better access to high quality medicines in the future”.

About the EGA (European Generic and Biosimilar medicines Association)
The EGA represents the European generic, biosimilar and value-added medicines industries, which provide high-quality cost-competitive medicines to millions of European patients. Companies represented within the EGA provide over 160,000 skilled, high value direct jobs in Europe. Without generic medicines, payers in Europe would have had to pay €100 billion more in 2014. Generic medicines account for 56% of all dispensed medicines but for only 22% of the pharmaceutical expenditure in Europe. The European generic and biosimilar medicines industries’ vision is to provide sustainable access to high quality medicines for all European patients, based on 5 important pillars: patients, quality, value, sustainability and partnership. For more information please follow EGA at and on twitter @egagenerics and@ebgbiosimilars.